Other languages Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
5.2 ^USD	-4.41%		+1.96%	-33.25%

09/04	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
09/04	Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	10/04
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	09/04
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene	25/03
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial	25/03
Sector Update: Health Care Stocks Mixed Late Afternoon	07/12
Sector Update: Health Care	07/12
Top Midday Gainers	07/12
Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine	06/12
Top Premarket Decliners	27/11
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Top Premarket Gainers	17/23/17
Sector Update: Health Care Stocks Lower Late Afternoon	03/23/03
Sector Update: Health Care Stocks Retreating Monday Afternoon	02/23/02
Syros Pharmaceuticals Names New CEO; to Cut Staff by 35%; Shares Drop	02/23/02
Syros Pharmaceuticals, Inc. Announces Management Changes	02/23/02
Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023	02/23/02
Syros Pharmaceuticals, Inc. Receives Notice from Incyte Corporation to Terminate the Target Discovery, Research Collaboration and Option Agreement	12/23/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Other languages

Filters